Michael Wyzga
Président chez X4 PHARMACEUTICALS, INC.
Fortune : 86 634 $ au 30/04/2024
Profil
Michael S.
Wyzga founded Bioleap, Inc. (Florida) in 2013, where he is working as President from 2021.
Mr. Wyzga also founded Sporos Bioventures, Inc., where he is working as Chairman & Chief Financial Officer.
Mr. Wyzga also currently works at Gensight Biologics SA, as Chairman from 2016, Mereo BioPharma Group Plc, as Chairman from 2022, X4 Pharmaceuticals, Inc., as Independent Chairman from 2018, International Institute of New England, Inc., as Director, Dohmen Co., as Director from 2010, Tvardi Therapeutics, Inc., as Director from 2021, Glyscend, Inc., as Director from 2023, Invivyd, Inc., as Independent Director from 2021, and Carina Biotech Pty Ltd., as Independent Director from 2023.
Mr. Wyzga also formerly worked at Radius Health, Inc., as President, Chief Executive Officer & Director from 2011 to 2013, Arsanis, Inc., as Chairman, X4 Pharmaceuticals, Inc., as Chairman, EXACT Sciences Corp., as Independent Director from 2015 to 2021, Idenix Pharmaceuticals LLC, as Independent Director from 2012 to 2014, OncoMed Pharmaceuticals, Inc., as Independent Director from 2013 to 2019, Altus Pharmaceuticals, Inc., as Director from 2004 to 2009, Akebia Therapeutics, Inc., as Independent Director from 2014 to 2018, The Wang Center For The Performing Arts, Inc., as Director, LogicBio Therapeutics, Inc., as Independent Director from 2018 to 2022, Digital Equipment Corp., as Principal, Lotus Development Corp., as Vice President-Finance in 1997, Genzyme Corp., as Chief Financial Officer & Executive VP-Finance from 2003 to 2011, Aura Biosciences, Inc., as Chief Financial Officer from 2011 to 2013, Sovereign Hill Software, Inc., as Chief Financial Officer from 1997 to 1998, Prosensa Holding NV, as Member-Supervisory Board in 2014, CacheLink Corp., as Chief Financial Officer & Vice President in 1997, and Kew, Inc., as Chief Financial Officer.
Mr. Wyzga received his undergraduate degree from Suffolk University and Masters Business Admin degree from Providence College.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
X4 PHARMACEUTICALS, INC.
0,05% | 18/08/2023 | 76 667 ( 0,05% ) | 86 634 $ | 30/04/2024 |
INVIVYD, INC.
-.--% | 22/03/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
| 08/02/2024 | 0 ( -.--% ) | - $ | 30/04/2024 |
Postes actifs de Michael Wyzga
| Sociétés | Poste | Début |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Président | 01/02/2016 |
| X4 PHARMACEUTICALS, INC. | Président | 01/07/2018 |
| MEREO BIOPHARMA GROUP PLC | Président | 17/05/2022 |
| INVIVYD, INC. | Directeur/Membre du Conseil | 29/07/2021 |
Glyscend, Inc.
 Glyscend, Inc. Pharmaceuticals: MajorHealth Technology Glyscend, Inc. engages in the development of therapeutics for treating metabolic diseases. It focuses on providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. The company was founded by Kevin Colbert in September 2014 and is headquartered in Baltimore, MD. | Directeur/Membre du Conseil | 30/03/2023 |
Sporos Bioventures, Inc.
 Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Fondateur | - |
Tvardi Therapeutics, Inc.
 Tvardi Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX. | Directeur/Membre du Conseil | 11/03/2021 |
Bioleap, Inc. (Florida)
 Bioleap, Inc. (Florida) Engineering & ConstructionIndustrial Services Bioleap, Inc. is an engineering services company based in Tampa, FL. Bioleap, Inc. provides engineering services. The private company was founded by Michael S. Wyzga. | Fondateur | 01/11/2013 |
International Institute of New England, Inc.
 International Institute of New England, Inc. Services to the Health IndustryHealth Services International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA. | Directeur/Membre du Conseil | - |
| ░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Anciens postes connus de Michael Wyzga
| Sociétés | Poste | Fin |
|---|---|---|
| ░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░ ░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ ░░░░░░░░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░ ░░░░░░░ ░░ | ░░░░░░░░░░░░░░░░ ░░ ░░░░░░░ | ░░░░░░░░░░ |
Formation de Michael Wyzga
| Suffolk University | Undergraduate Degree |
| Providence College | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 7 |
|---|---|
| AKEBIA THERAPEUTICS, INC. | Health Technology |
| EXACT SCIENCES CORPORATION | Health Technology |
| GENSIGHT BIOLOGICS S.A. | Health Technology |
| AURA BIOSCIENCES, INC. | Health Technology |
| X4 PHARMACEUTICALS, INC. | Health Technology |
| MEREO BIOPHARMA GROUP PLC | Health Technology |
| INVIVYD, INC. | Health Technology |
| Entreprise privées | 22 |
|---|---|
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Altus Pharmaceuticals, Inc. develops therapeutic products for gastrointestinal and metabolic diseases. Its principal activity is protein crystallization which is used to develop therapeutic products for gastrointestinal and metabolic diseases. The company was founded in October 1992 and is headquartered in Waltham, MA. | Health Technology |
Sovereign Hill Software, Inc.
 Sovereign Hill Software, Inc. Packaged SoftwareTechnology Services Part of LeadingSide, Inc., Sovereign Hill Software, Inc. supplies next generation software products. The company is based in Hadley, MA. Sovereign Hill Software was acquired by LeadingSide, Inc. on January 04, 1999 for $1.70 million. | Technology Services |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
| CacheLink Corp. | |
| Digital Equipment Corp. | Electronic Technology |
Lotus Development Corp.
 Lotus Development Corp. Packaged SoftwareTechnology Services Lotus Development Corp. was an American software company. The company was famous for their groundbreaking Lotus 1-2-3 spreadsheet application, which was the killer application in the early days of the IBM PC which helped spread the adoption of the PC. The company also provided one of the more powerful groupware systems, Lotus Notes. The company was headquartered in Cambridge, MA | Technology Services |
Idenix Pharmaceuticals LLC
 Idenix Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Idenix Pharmaceuticals LLC is a biopharmaceutical company, which is engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and France. Currently, its primary research and development focus is on the treatment of patients with hepatitis C virus, or HCV, using nucleotide polymerase inhibitors and NS5A inhibitors. Idenix Pharmaceuticals was founded by Jean-Pierre Sommadossi and Raymond F. Schinazi in May 1998 and is headquartered in Cambridge, MA. | Health Technology |
OncoMed Pharmaceuticals, Inc.
 OncoMed Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology OncoMed Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which focuses on discovering and developing novel therapeutics for cancer's growth, resistance, recurrence and metastasis. The company was founded by Michael F. Clarke and Max Wicha in August 2004 and is headquartered in Redwood City, CA. | Health Technology |
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Prosensa Holding NV engages in the development of ribonucleic acid-modulating, or RNA-modulating, therapeutics for the treatment of genetic disorders. The company focuses on rare neuromuscular and neurodegenerative disorders, Duchenne muscular dystrophy, myotonic dystrophy and Huntington's disease. It has developed a portfolio of clinical and pre-clinical RNA-based drug candidates. Prosensa's current clinical portfolio is focused on the treatment of Duchenne Muscular Dystrophy. The company was founded in 2002 and is headquartered in Leiden, the Netherlands. | Health Technology |
Dohmen Co.
 Dohmen Co. Data Processing ServicesTechnology Services Dohmen Co. operates as a retail pharmacy agency that provides outsourced healthcare services. Its services include supply chain, customer and patient support, technology, financial, consulting, and quality and regulatory services. The company was founded by Friedrich W. Dohmen in 1858 and is headquartered in Milwaukee, WI. | Technology Services |
The Wang Center For The Performing Arts, Inc.
 The Wang Center For The Performing Arts, Inc. Internet Software/ServicesTechnology Services Boch Center is a Non-Profit Organisation, which provides arts, entertainment, cultural and educational experience. The company is headquartered in Boston, MA. | Technology Services |
Kew, Inc.
 Kew, Inc. Medical/Nursing ServicesHealth Services Kew, Inc. provides oncology services. It provides multiple services to oncologists to assist in treatment decisions for cancer patients and offers genomic testing for patient tumor samples and genomic information important to diagnostic and treatment decisions that assist physicians and are detailed in cancer-specific Therapeutic Pathways. The company was founded by Richard Bohmer, Viren Mehta, Clayton Matt Christensen, Jeffrey Elton, Mason Freeman, John P. Glaser, H. Robert Horvitz, Bruce Johnson, Kathy Behrens Wilsey and Raju S. Kucherlapat in 2009 and is headquartered in Cambridge, MA. | Health Services |
International Institute of New England, Inc.
International Institute of New England, Inc. Services to the Health IndustryHealth Services International Institute of New England, Inc. operates as a non-profit organization serving immigrants, refugees, asylees, and other vulnerable populations. Its services include refugee resettlement, case management, health services navigation, employment, education and literacy and citizenship programming. The company was founded in 1910 and is headquartered in Boston, MA. | Health Services |
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | Health Technology |
LogicBio Therapeutics, Inc.
 LogicBio Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline includes LB-001, LB-301 and LB-401. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Lexington, MA. | Health Technology |
Bioleap, Inc. (Florida)
Bioleap, Inc. (Florida) Engineering & ConstructionIndustrial Services Bioleap, Inc. is an engineering services company based in Tampa, FL. Bioleap, Inc. provides engineering services. The private company was founded by Michael S. Wyzga. | Industrial Services |
Arsanis, Inc.
 Arsanis, Inc. BiotechnologyHealth Technology Arsanis, Inc. operates as a clinical-stage biotechnology company, which engages in provision of monoclonal antibody immunotherapies to address serious infectious diseases. The company was founded by Eszter Nagy, Tillman U. Gerngross, and Errik B. Anderson on August 2, 2010 and is headquartered in Waltham, MA. | Health Technology |
Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Tvardi Therapeutics, Inc. develops and commercializes medicines for the treatment of diverse cancers, chronic inflammatory and fibrotic diseases. The company was founded by David J. Tweardy and Ronald A. DePinho in 2017 and is headquartered in Houston, TX. | Commercial Services |
Sporos Bioventures, Inc.
Sporos Bioventures, Inc. Medical/Nursing ServicesHealth Services Sporos Bioventures, Inc. is a private biopharmaceutical company based in Houston, TX. Sporos Bioventures, Inc. aims to transform the drug development process by identifying novel disease mechanisms and strategically deploying talent, capital, and access to operational resources to catalyze the development of breakthrough medicines. Sporos' current pipeline is diversified across three business units and includes multiple clinical-stage candidates that are being investigated for the treatment of multiple indications in cancer and immune disease. The company provides centralized expertise, resources, and core infrastructure so that the portfolio companies can focus primarily on their research development programs. The company was founded by Peter Feinberg, Ronald A. DePinho, Jeno Gyuris, Joseph Kekst, Harold Levy, Alex M. Cranberg, Louis Feinberg, Michael S. Wyzga, Dana Levy, and the CEO is Stephen Rubino. | Health Services |
Glyscend, Inc.
Glyscend, Inc. Pharmaceuticals: MajorHealth Technology Glyscend, Inc. engages in the development of therapeutics for treating metabolic diseases. It focuses on providing patients with an effective strategy to keep glucose levels under control and eliminate potential side effects like weight gain and hypoglycemia. The company was founded by Kevin Colbert in September 2014 and is headquartered in Baltimore, MD. | Health Technology |
Carina Biotech Pty Ltd.
 Carina Biotech Pty Ltd. BiotechnologyHealth Technology Carina Biotech Pty Ltd. is an immuno-oncology company based in Mawson Lakes, Australia. The Australian company is developing CAR-T and other adoptive cell therapies to treat solid cancers. Carina Biotech has a deep pipeline of CAR-T programs, including its LGR5-targeted CAR-T cell therapy CNA3103 for advanced colorectal cancer. The private company aims to improve access to and infiltration of solid cancers by CAR-containing cells, resulting in more potent and specific cancer killing and reduced off-target effects. Carina Biotech also has a fully integrated, proprietary manufacturing process that has both reduced manufacturing time and improved CAR-T cell quality, capable of delivering robust “serial-killing” CAR-T cells to patients. The CEO of the company is Deborah A. Rathjen. | Health Technology |